Advertisement

Topics

Cerulean Announces $20 Million Firm Commitment At-The-Market Stock Purchase Agreement with Aspire Capital Fund, LLC

12:46 EDT 19 Oct 2016 | Biotech-Finances

Wednesday, October 19th 2016 at 12:00pm UTC Initial purchase of 800,000 shares of common stock for $1.25 per share WALTHAM, Mass.–(BUSINESS WIRE)– Cerulean Pharma Inc. (NASDAQ:CERU), a clinical-stage company developing nanoparticle-drug conjugates (NDCs), today announced that it has entered into a $20 million common stock purchase agreement (Purchase Agreement) and a registration rights agreement (Registration …

Cet article Cerulean Announces $20 Million Firm Commitment At-The-Market Stock
Purchase Agreement with Aspire Capital Fund, LLC
est apparu en premier sur EEI-BIOTECHFINANCES.

Original Article: Cerulean Announces $20 Million Firm Commitment At-The-Market Stock Purchase Agreement with Aspire Capital Fund, LLC

NEXT ARTICLE

More From BioPortfolio on "Cerulean Announces $20 Million Firm Commitment At-The-Market Stock Purchase Agreement with Aspire Capital Fund, LLC"

Quick Search
Advertisement
 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...